AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20850381 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin alone
Number of subjects: 205
Study 18235121 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg/d
Number of subjects: 147
Study 18235121 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 600 mg/d
Number of subjects: 147
Study 18235121 — intervention group
Group type: COMPARATOR
Intervention: Both doses (400 mg/d and 600 mg/d)
Number of subjects: 147
Study 15783259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15783259 — intervention group
Group type: EXPERIMENTAL
Intervention: Proven effective therapy
Number of subjects: 0
Study 15783259 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo trials
Number of subjects: 0
Study 12020263 — intervention group
Group type: EXPERIMENTAL
Intervention: Budipine 20 mg, 3 times daily
Number of subjects: 99
Study 12020263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 10217608 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection
Number of subjects: 252
Study 10217608 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous injection
Number of subjects: 252
Study 10217608 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 252
Study 7883776 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesna administration (Arm A: i.v. in equal doses 15 min before and 4 h and 8 h after ifosfamide; Arm B: three equivalent doses 15 min before (i.v.) and 4 h (i.v.) and 8 h (p.o., double dose); Arm C: i.v. in two equal doses 15 min before and 4 h after).
Number of subjects: 122
Study 2204854 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate aspirated from the anterior chamber prior to wound closure
Number of subjects: 99
Study 2204854 — intervention group
Group type: COMPARATOR
Intervention: Sodium hyaluronate not aspirated from the anterior chamber
Number of subjects: 99
Study 2204854 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (aspirated and not-aspirated)
Number of subjects: 99
Study 43585 — intervention group
Group type: EXPERIMENTAL
Intervention: methyl-salazosulphapyridine (125 mg x 3 daily)
Number of subjects: 53
Study 43585 — intervention group
Group type: COMPARATOR
Intervention: salazosulphapyridine (1 g x 3 daily)
Number of subjects: 53
Study 31682972 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS administration
Number of subjects: 120
Study 31682972 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 120
Study 31682972 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline inflammatory markers
Number of subjects: 120
Study 31685496 — intervention group
Group type: EXPERIMENTAL
Intervention: 25° head-up position
Number of subjects: 1000
Study 31685496 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 1000
Study 30261836 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartMan mHealth system
Number of subjects: 120
Study 28827261 — intervention group
Group type: EXPERIMENTAL
Intervention: McGrath video laryngoscope
Number of subjects: 2000
Study 28827261 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 2000
Study 26637340 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus a 12-week supervised exercise program
Number of subjects: 0
Study 26637340 — intervention group
Group type: COMPARATOR
Intervention: Usual outpatient care alone
Number of subjects: 0
Study 24028354 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication reviews performed by a physician
Number of subjects: 199
Study 24028354 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians' attitudes toward the intervention
Number of subjects: 199
Study 21712483 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring tendon autograft (semitendinosus and gracilis)
Number of subjects: 64
Study 21712483 — intervention group
Group type: COMPARATOR
Intervention: Patellar tendon autograft
Number of subjects: 64
Study 18850550 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof SN60AT (spheric lenses)
Number of subjects: 69
Study 18850550 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof IQ SN60WF (aspheric lenses)
Number of subjects: 69
Study 18850550 — intervention group
Group type: COMPARATOR
Intervention: Natural crystalline lenses
Number of subjects: 69
Study 17027369 — intervention group
Group type: EXPERIMENTAL
Intervention: BMP15 gene mutations screening
Number of subjects: 0
Study 17027369 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 12779351 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrectomy followed by treatment with interferon alfa‐2b
Number of subjects: 0
Study 12779351 — intervention group
Group type: COMPARATOR
Intervention: Treatment with interferon alfa‐2b alone
Number of subjects: 0
Study 10845018 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% diclofenac
Number of subjects: 90
Study 10845018 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 10845018 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% indomethacin
Number of subjects: 90
Study 10845018 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% flurbiprofen
Number of subjects: 90
Study 10845018 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ketorolac
Number of subjects: 90
Study 10845018 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% oxybuprocaine
Number of subjects: 90
Study 9170825 — intervention group
Group type: COMPARATOR
Intervention: Dinoprostone vaginal tablets
Number of subjects: 60
Study 9170825 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol vaginal tablets
Number of subjects: 60
Study 8362631 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 second argon laser trabeculoplasty
Number of subjects: 0
Study 8362631 — intervention group
Group type: COMPARATOR
Intervention: 0.1 second argon laser trabeculoplasty
Number of subjects: 0
Study 8362631 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (0.1 second and 0.2 second)
Number of subjects: 0
Study 4027102 — intervention group
Group type: EXPERIMENTAL
Intervention: MST Continus 20 mg (oral morphine)
Number of subjects: 80
Study 4027102 — intervention group
Group type: COMPARATOR
Intervention: i.m. morphine 10 mg
Number of subjects: 80
Study 30907200 — intervention group
Group type: EXPERIMENTAL
Intervention: cGCE
Number of subjects: 16
Study 30907200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 29546298 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 L semiskimmed milk/wk
Number of subjects: 78
Study 29546298 — intervention group
Group type: COMPARATOR
Intervention: Usual milk consumption (baseline median: 140 mL/d; IQR: 40‐240 mL/d)
Number of subjects: 78
Study 26893546 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimatrix mesalamine 30 mg/kg/day
Number of subjects: 52
Study 26893546 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimatrix mesalamine 60 mg/kg/day
Number of subjects: 52
Study 26893546 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimatrix mesalamine 100 mg/kg/day
Number of subjects: 52
Study 26893546 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimatrix mesalamine (all doses)
Number of subjects: 52
Study 26689369 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple imputation (MI) using multiple agglomerative hierarchical clustering
Number of subjects: 0
Study 26689369 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple imputation (MI) using normal distribution model
Number of subjects: 0
Study 26689369 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple imputation (MI) using normal regression model
Number of subjects: 0
Study 26689369 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple imputation (MI) using predictive mean match
Number of subjects: 0
Study 26689369 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian analysis models
Number of subjects: 0
Study 26689369 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Bayesian analysis models
Number of subjects: 0
Study 21773858 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine artery embolization (UAE)
Number of subjects: 163
Study 21773858 — intervention group
Group type: COMPARATOR
Intervention: Myomectomy
Number of subjects: 163
Study 20610636 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D insufficiency (serum 25(OH)D concentration < 30 ng/mL)
Number of subjects: 95
Study 20610636 — intervention group
Group type: EXPERIMENTAL
Intervention: LL-37 concentrations
Number of subjects: 95
Study 20610636 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of LL-37 concentrations
Number of subjects: 95
Study 20610636 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum vitamin D status
Number of subjects: 95
Study 18331221 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% water solution of sucrose (CHO; 4 kcal/kg body mass)
Number of subjects: 14
Study 18331221 — intervention group
Group type: COMPARATOR
Intervention: Equal volume of water (control)
Number of subjects: 14
Study 15980352 — intervention group
Group type: COMPARATOR
Intervention: 873140 50 mg to 800 mg single dose
Number of subjects: 70
Study 15980352 — intervention group
Group type: COMPARATOR
Intervention: 873140 200 mg to 800 mg repeat dose (BID for 8 days)
Number of subjects: 70
Study 15980352 — intervention group
Group type: EXPERIMENTAL
Intervention: Food consumption with 400 mg dose
Number of subjects: 70
Study 15980352 — intervention group
Group type: COMPARATOR
Intervention: 873140 200 mg BID
Number of subjects: 70
Study 15980352 — intervention group
Group type: COMPARATOR
Intervention: 873140 800 mg BID
Number of subjects: 70
Study 12680865 — intervention group
Group type: EXPERIMENTAL
Intervention: Mite allergen‐impermeable mattress encasings
Number of subjects: 810
Study 12680865 — intervention group
Group type: COMPARATOR
Intervention: Placebo mattress encasings
Number of subjects: 810
Study 10868525 — intervention group
Group type: EXPERIMENTAL
Intervention: BM+PBPC
Number of subjects: 27
Study 10868525 — intervention group
Group type: COMPARATOR
Intervention: BM
Number of subjects: 27
Study 7854545 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with Parkinson's disease
Number of subjects: 32
Study 7854545 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 32
Study 3291223 — intervention group
Group type: EXPERIMENTAL
Intervention: Cs monotherapy (8 to 10 mg/kg/d)
Number of subjects: 110
Study 3291223 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy (Cs, azathioprine, and prednisolone or Cs and azathioprine)
Number of subjects: 110
Study 766879 — intervention group
Group type: EXPERIMENTAL
Intervention: Wistar RA 27/3 vaccine
Number of subjects: 1525
Study 766879 — intervention group
Group type: COMPARATOR
Intervention: Cendehill strain live attenuated vaccine
Number of subjects: 1525
Study 31192834 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender oil aromatherapy
Number of subjects: 60
Study 31192834 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aromatherapy)
Number of subjects: 60
Study 28283752 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative immune-modulating diet (IMD)
Number of subjects: 30
Study 28283752 — intervention group
Group type: COMPARATOR
Intervention: Standard liquid diet (SLD)
Number of subjects: 30
Study 26904891 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium alginate wound dressings with hemostatic gauze pad (Group C)
Number of subjects: 997
Study 26904891 — intervention group
Group type: COMPARATOR
Intervention: Gauze pad (Group A)
Number of subjects: 997
Study 26904891 — intervention group
Group type: COMPARATOR
Intervention: Calcium alginate wound dressings (Group B)
Number of subjects: 997
Study 23932803 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin users
Number of subjects: 83953
Study 23932803 — intervention group
Group type: EXPERIMENTAL
Intervention: Other cholesterol-lowering medications
Number of subjects: 83953
Study 23932803 — intervention group
Group type: COMPARATOR
Intervention: No cholesterol-lowering agents (Control group)
Number of subjects: 83953
Study 21531082 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with AN before weight gain
Number of subjects: 30
Study 21531082 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with AN after weight gain
Number of subjects: 30
Study 21531082 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group (CG)
Number of subjects: 30
Study 18155058 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (5 mg/kg bolus dose)
Number of subjects: 50
Study 18155058 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine with epinephrine (5 mcg/mL)
Number of subjects: 50
Study 18155058 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Lidocaine and Lidocaine with epinephrine
Number of subjects: 50
Study 20617345 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially-based drink (Moove™)
Number of subjects: 59
Study 20617345 — intervention group
Group type: COMPARATOR
Intervention: Hospital-prepared supplements
Number of subjects: 59
Study 20617345 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially available supplements
Number of subjects: 59
Study 20617345 — intervention group
Group type: COMPARATOR
Intervention: Hospital supplements
Number of subjects: 59
Study 16136764 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl chloride
Number of subjects: 20
Study 16136764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12002666 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of latanoprost 0.005% and timolol 0.5%
Number of subjects: 0
Study 12002666 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost monotherapy
Number of subjects: 0
Study 12002666 — intervention group
Group type: COMPARATOR
Intervention: Timolol monotherapy
Number of subjects: 0
Study 10408664 — intervention group
Group type: EXPERIMENTAL
Intervention: Gutter frame
Number of subjects: 27
Study 10408664 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimmer frame
Number of subjects: 27
Study 10408664 — intervention group
Group type: COMPARATOR
Intervention: Unaided walk
Number of subjects: 27
Study 10408664 — intervention group
Group type: EXPERIMENTAL
Intervention: Rollator frame
Number of subjects: 27
Study 8071762 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzathine penicillin G
Number of subjects: 169
Study 8071762 — intervention group
Group type: COMPARATOR
Intervention: Procaine penicillin G
Number of subjects: 169
Study 2847079 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg IM daily of purified bovine brain gangliosides (Cronassial)
Number of subjects: 76
Study 2847079 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg IM daily of purified bovine brain gangliosides (Cronassial)
Number of subjects: 76
Study 2847079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 4445714 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice
Number of subjects: 0
Study 4445714 — intervention group
Group type: EXPERIMENTAL
Intervention: Short wave diathermy
Number of subjects: 0
Study 4445714 — intervention group
Group type: COMPARATOR
Intervention: Untuned short wave diathermy
Number of subjects: 0
Study 31282101 — intervention group
Group type: EXPERIMENTAL
Intervention: VTE prophylaxis continued
Number of subjects: 351
Study 31282101 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in VTE risk category
Number of subjects: 351
Study 31282101 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in bleed risk category
Number of subjects: 351
Study 31282101 — intervention group
Group type: EXPERIMENTAL
Intervention: VTE RAMs usage
Number of subjects: 351
Study 29584916 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical lysis of fibrotic tissue in the epidural space
Number of subjects: 48
Study 29584916 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase and corticosteroid methylprednisolone acetate during the procedure
Number of subjects: 48
Study 29584916 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 48
Study 27424614 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphadoxine-pyrimethamine (SP)
Number of subjects: 200
Study 27424614 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (AZ)
Number of subjects: 200
Study 27424614 — intervention group
Group type: COMPARATOR
Intervention: Both SP and AZ
Number of subjects: 200
Study 24927471 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet treatment (NET)
Number of subjects: 52
Study 24927471 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (WLC)
Number of subjects: 52
Study 22616078 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone for 2 weeks and intranasal budesonide for 12 weeks
Number of subjects: 0
Study 22616078 — intervention group
Group type: COMPARATOR
Intervention: Control group (no steroid treatment)
Number of subjects: 0
Study 19898966 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous levetiracetam (LEV)
Number of subjects: 52
Study 17852670 — intervention group
Group type: EXPERIMENTAL
Intervention: Very high molecular weight glucose polymer solution
Number of subjects: 8
Study 17852670 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight glucose polymer solution
Number of subjects: 8
Study 17852670 — intervention group
Group type: COMPARATOR
Intervention: Sugar-free flavoured water (control)
Number of subjects: 8
Study 16156505 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 141
Study 16156505 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 141
Study 11788414 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic (spironolactone: 100 mg/day, 3 days)
Number of subjects: 8
Study 11788414 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normovolemia)
Number of subjects: 8
Study 10412846 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescored plaque index from previously recorded plaque areas
Number of subjects: 0
Study 10412846 — intervention group
Group type: EXPERIMENTAL
Intervention: Original plaque index scores
Number of subjects: 0
Study 10412846 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaque area measurements
Number of subjects: 0
Study 10412846 — intervention group
Group type: EXPERIMENTAL
Intervention: Original plaque index derived from buccal surfaces of all teeth
Number of subjects: 0
Study 7539609 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose aprotinin
Number of subjects: 40
Study 7539609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 2110425 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.16 mg/kg) with flumazenil (0.55 mg)
Number of subjects: 60
Study 2110425 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (1.50 mg/kg)
Number of subjects: 60
Study 2110425 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (0.16 mg/kg)
Number of subjects: 60
Study 383023 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalorphine IV
Number of subjects: 85
Study 383023 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone IV (0.01 mg/kg)
Number of subjects: 85
Study 383023 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone IV (0.02 mg/kg)
Number of subjects: 85
Study 383023 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antagonist)
Number of subjects: 85
Study 30600153 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Decalogue aid
Number of subjects: 100
Study 30600153 — intervention group
Group type: COMPARATOR
Intervention: Overall educational intervention
Number of subjects: 100
Study 25775165 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle arm
Number of subjects: 3234
Study 25775165 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin arm
Number of subjects: 3234
Study 25775165 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo arm
Number of subjects: 3234
Study 25775165 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalization of FPG
Number of subjects: 3234
Study 25775165 — intervention group
Group type: COMPARATOR
Intervention: Overall findings
Number of subjects: 3234
Study 23389823 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonanalytic group (25 participants)
Number of subjects: 49
Study 23389823 — intervention group
Group type: COMPARATOR
Intervention: Analytic group (24 participants)
Number of subjects: 49
Study 23389823 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 49
Study 21551966 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy using dual-agent injection of blue dye and radioactive colloid
Number of subjects: 253
Study 21551966 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy
Number of subjects: 253
Study 21551966 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy without axillary lymph node dissection
Number of subjects: 253
Study 19873708 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopy-assisted partial-superficial parotidectomy
Number of subjects: 38
Study 19873708 — intervention group
Group type: COMPARATOR
Intervention: Conventional partial-superficial parotidectomy
Number of subjects: 38
Study 17442659 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate 50 mg/day
Number of subjects: 275
Study 17442659 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic acid 4 mg every 4 weeks
Number of subjects: 275
Study 14696020 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine (120 mg)
Number of subjects: 11
Study 14696020 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine (10 mg)
Number of subjects: 11
Study 14696020 — intervention group
Group type: EXPERIMENTAL
Intervention: d-chlorpheniramine (4 mg)
Number of subjects: 11
Study 14696020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 10777122 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 36
Study 10777122 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CyA)
Number of subjects: 36
Study 8639180 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-10
Number of subjects: 0
Study 8639180 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-4
Number of subjects: 0
Study 8639180 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-10 and IL-4 (combination)
Number of subjects: 0
Study 1600042 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 2.5 mg three times daily for 7 days
Number of subjects: 25